Considerations of Particle Analysis (12of35) Complex Generics - Sep. 25-26, 2019

Xiaoming Xu from the CDER Office of Pharmaceutical Division of Product Quality provides an overview of research, development, characterization, and evaluation of particle analysis to support generic product quality and bioequivalence determination.
Learn more at www.fda.gov/dr...
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Visit www.fda.gov/cd... and www.fda.gov/cd... for news and a repository of training activities.
Email: [e-mail]
Phone: [phone] I [phone]
LinkedIn: / cder-small-business-an...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...